The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

4 months ago

Version History

Version 14 months ago

What changed: The story was updated to include ADMA Biologics management's formal pushback against short-seller allegations and their emphasis on steady operational fundamentals.

StocksUpdated•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

Stock Performance Divergence: ADMA Plunges as Kinross Gold Surges on Record Prices

Key Facts

1ADMA stock plunged 42.5% YTD following a short report, despite strong demand for its Asceniv product.

2Kinross Gold (KGC) shares surged 126% over a year driven by record gold prices and margin expansion.

Equity markets are witnessing a sharp divergence as ADMA Biologics shares remain down 42.5% year-to-date following a targeted short-seller report. In response, ADMA management is actively pushing back against the allegations, citing steady fundamental performance and robust demand for its core product, Asceniv. Conversely, Kinross Gold (KGC) has surged 126% over the past year, fueled by record-breaking gold prices and significant margin expansion. While ADMA faces the challenge of restoring investor confidence through its operational strength, Kinross continues to capitalize on the broader bullion bull market. Investors are now weighing management's defense of ADMA's growth story against the momentum-driven gains of KGC. The market remains focused on whether fundamental resilience can overcome short-selling pressure in the biotech sector.

Sources:

zacks.com